<DOC>
	<DOCNO>NCT02428491</DOCNO>
	<brief_summary>The purpose study describe immunogenicity safety Sanofi Pasteur 's DTaP-IPV-Hep B-PRP-T fully liquid combine hexavalent vaccine ( Hexaxim® ) administer 2 , 3 , 4 month age 16 17 month age infants toddler receive dose Hep B vaccine birth within 1 week birth . Primary Objective : - To describe safety profile dose Sanofi-Pasteur 's DTaP-IPV-Hep B-PRP-T combine vaccine Vietnamese infant toddler Secondary Objective : - To evaluate immunogenicity study vaccine one month third dose primary series . - To demonstrate non-inferiority immune response antigen induce study vaccine Vietnamese infant one month third dose 3 dose primary series immune response antigens induced study vaccine outside Vietnam - To describe persistence antibody receipt booster vaccination .</brief_summary>
	<brief_title>Study Sanofi Pasteur 's DTaP-IPV Hep B-PRP-T Combined Vaccine Infants Who Previously Received Hepatitis B Vaccine</brief_title>
	<detailed_description>Participants receive total 5 dos Hep B : One dose Hep B monovalent vaccine give birth within 1 week birth follow 3 dos Sanofi Pasteur 's hexavalent vaccine give 2 , 3 , 4 month age ( Primary Series ) ( 16 17 month age [ booster ] ) comply Vietnamese vaccination recommendation .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 61 91 day day first study visit Born full term pregnancy ( ≥ 37 week ) birth weight ≥2.5 kg Informed consent form sign dated parent ( ) legally acceptable representative ( independent witness require local regulation ) Subject parent/legally acceptable representative able attend schedule visit comply trial procedure Have receive one dose Hep B vaccine birth within 1 week birth ( document accord national recommendation ) . Participation 4 week precede first trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede first trial vaccination plan receipt vaccine within period 8 day 8 day subsequent trial vaccination except Bacille Calmette Guerin ( BCG ) vaccination ( administration oral poliovirus vaccine ( OPV ) context oral poliovirus vaccinenational immunization day ( NIDs ) fall within scope exclusion criterion ) Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B ( except dose Hep B vaccine give birth within 1 week birth ) diseases Haemophilus influenzae type b infection either trial vaccine another vaccine ( administration OPV context OPVNIDs fall within scope exclusion criterion ) Past current receipt immune globulin , blood bloodderived product plan administration trial Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy , anticancer chemotherapy radiation therapy since birth ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week since birth ) History diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B , Haemophilus influenzae type b infection ( confirm either clinically , serologically microbiologically ) Known personal maternal history Human Immunodeficiency Virus ( HIV ) , hepatitis C seropositivity Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known thrombocytopenia , report parent/legally acceptable representative Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination History seizures In emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( temperature ≥38.0°C ) . A prospective subject include study condition resolve febrile event subside Identified natural adopt child Investigator , relatives employee direct involvement propose study .</criteria>
	<gender>All</gender>
	<minimum_age>61 Days</minimum_age>
	<maximum_age>91 Days</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Poliomyelitis</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>DTaP-IPV-Hep B-PRP-T Combined Vaccine ( Hexaxim™ )</keyword>
</DOC>